DPP4

(redirected from Dipeptidyl Peptidase IV)
Also found in: Acronyms.

DPP4

A gene on chromosome 2q24.3 that encodes dipeptidyl-peptidase 4, a ubiquitous, membrane-bound enzyme with roles in nutrition, metabolism, the endocrine system, immune regulation (for instance, it is essential for T-cell receptor (TCR)-mediated T-cell activation), bone marrow mobilisation, apoptosis, cell adhesion and tumourigenesis.
References in periodicals archive ?
Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes.
Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Chapter 12: Dipeptidyl peptidase IV inhibitors for treatment of diabetes (McIntosh, CHS, Kim, S-J.
Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
is a dipeptidyl peptidase IV (DPP-4) inhibitor for the treatment of type 2 diabetes.
rights to potential future regulatory and sales-based milestones and, if approved, royalties on sales for Takeda Pharmaceutical Company Limited's dipeptidyl peptidase IV (DPP-4) inhibitor, alogliptin, for which the FDA issued a complete response letter in June 2009 and requested Takeda conduct an additional cardiovascular safety trial to satisfy the FDA's December 2008 guidance on anti-diabetic therapies;
is a dipeptidyl peptidase IV (DPP-4) inhibitor being reviewed as an adjunct to diet and exercise for the treatment of type 2 diabetes.
PPD is partnering with Takeda to develop alogliptin, a selective dipeptidyl peptidase IV (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Alogliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor discovered by Takeda's wholly owned U.
24 /PRNewswire/ -- Alantos Pharmaceuticals, a privately held biopharmaceutical company based on the discovery and development of small molecule drugs with a focus on type II diabetes and osteoarthritis/inflammation, today announced that it has formed a collaboration with Servier, the leading French independent pharmaceutical company, surrounding its lead compound ALS 2-0426, an orally active, small molecule inhibitor of Dipeptidyl Peptidase IV (DPP-IV), being developed for the treatment of type II diabetes.

Full browser ?